Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.

Kothari G, Ost P, Cheung P, Blanchard P, Tree AC, van As NJ, Lo SS, Moghanaki D, Loblaw A, Siva S.

Curr Oncol Rep. 2019 Mar 27;21(5):43. doi: 10.1007/s11912-019-0791-5. Review.

PMID:
30919165
2.

Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.

Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S.

Eur Urol Oncol. 2019 Mar;2(2):174-188. doi: 10.1016/j.euo.2018.09.005. Epub 2018 Oct 9. Review.

PMID:
31017094
3.

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.

Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG.

BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.

4.

Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.

Niazi T, Elakshar S, Stroian G.

Curr Opin Support Palliat Care. 2018 Sep;12(3):351-358. doi: 10.1097/SPC.0000000000000371.

PMID:
29979320
5.

Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.

Fleckenstein J, Petroff A, Schäfers HJ, Wehler T, Schöpe J, Rübe C.

BMC Cancer. 2016 Jun 2;16:348. doi: 10.1186/s12885-016-2379-x.

6.

Oligometastases in prostate cancer: Ablative treatment.

Palacios-Eito A, Béjar-Luque A, Rodríguez-Liñán M, García-Cabezas S.

World J Clin Oncol. 2019 Feb 24;10(2):38-51. doi: 10.5306/wjco.v10.i2.38. Review.

7.

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.

Kim J, Park JS, Ham WS.

Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8. Review.

8.

Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.

Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, van Moorselaar RJA, Piet MAH, Verberne HJ, Bins AD, Verheul HMW, Slotman BJ, Oprea-Lager DE, Van den Eertwegh AJM.

Clin Genitourin Cancer. 2017 Oct;15(5):e773-e782. doi: 10.1016/j.clgc.2017.03.009. Epub 2017 Mar 29.

PMID:
28462855
9.

A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?

Slaoui A, Albisinni S, Aoun F, Assenmacher G, Al Hajj Obeid W, Diamand R, Regragui S, Touzani A, Bakar A, Mesfioui A, Karmouni T, Ameur A, Elkhader K, Koutani A, Ibnattya A, Roumeguere T, Peltier A.

World J Urol. 2019 Jan 31. doi: 10.1007/s00345-019-02652-7. [Epub ahead of print]

PMID:
30706122
10.

Developments in oligometastatic hormone-sensitive prostate cancer.

Chow K, McCoy P, Stuchbery R, Corcoran NM, Hovens CM.

World J Urol. 2018 Oct 31. doi: 10.1007/s00345-018-2542-x. [Epub ahead of print]

PMID:
30382379
11.
12.

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer.

Miura Y, Horie S.

ESMO Open. 2019 Mar 12;4(Suppl 1):e000471. doi: 10.1136/esmoopen-2018-000471. eCollection 2019. Review.

13.

[Radiotherapy for local disease in metastatic prostate cancer.]

Cambeiro M, Calvo FA.

Arch Esp Urol. 2018 Mar;71(3):298-305. Review. Spanish.

PMID:
29633951
14.

Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.

Tsumura H, Ishiyama H, Tabata KI, Sekiguchi A, Kawakami S, Satoh T, Kitano M, Iwamura M.

Prostate. 2019 Apr;79(5):506-514. doi: 10.1002/pros.23757. Epub 2018 Dec 26.

PMID:
30585345
15.

Oligometastatic Prostate Cancer.

Navrátil J, Poprach A, Lakomý R, Kocák I, Vašina J, Krupa P, Vyzula R.

Klin Onkol. 2019 Spring;32(2):97-100. doi: 10.14735/amko201997.

PMID:
30995848
16.

Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer.

Clement JM, Sweeney CJ.

J Oncol Pract. 2017 Jan;13(1):9-18. doi: 10.1200/JOP.2016.018523. Epub 2017 Jan 3. Review.

PMID:
28045610
17.

Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.

Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, Alongi F, Del Conte A, Militello L, Muraro E, Martorelli D, Spazzapan S, Berretta M.

Radiother Oncol. 2018 Jan;126(1):177-180. doi: 10.1016/j.radonc.2017.08.032. Epub 2017 Sep 21.

PMID:
28943046
18.

Modeling growth kinetics and statistical distribution of oligometastases.

Withers HR, Lee SP.

Semin Radiat Oncol. 2006 Apr;16(2):111-9. Review.

PMID:
16564446
19.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
20.

OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.

Supiot S, Rio E, Pacteau V, Mauboussin MH, Campion L, Pein F.

BMC Cancer. 2015 Sep 25;15:646. doi: 10.1186/s12885-015-1579-0.

Supplemental Content

Support Center